The estimated Net Worth of Stephen J Farr is at least $12.9 Milhão dollars as of 15 March 2021. Stephen Farr owns over 16,875 units of Zogenix Inc stock worth over $2,486,896 and over the last 14 years he sold ZGNX stock worth over $43,890. In addition, he makes $10,346,800 as President, Chief Executive Officer, e Director at Zogenix Inc.
Stephen has made over 12 trades of the Zogenix Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 16,875 units of ZGNX stock worth $450,225 on 15 March 2021.
The largest trade he's ever made was exercising 90,313 units of Zogenix Inc stock on 10 January 2019 worth over $929,321. On average, Stephen trades about 9,318 units every 80 days since 2011. As of 15 March 2021 he still owns at least 93,212 units of Zogenix Inc stock.
You can see the complete history of Stephen Farr stock trades at the bottom of the page.
Dr. Stephen J. Farr Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Stephen J. Farr, Ph.D., is one of our co-founders and has served as our President and as a member of our board of directors since our inception in May 2006. Dr. Farr has served as our Chief Executive Officer since April 2015 and served as our Chief Operating Officer from our inception to March 2013. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer with responsibility for research and development as well as business development. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the area of biopharmaceutics. Dr. Farr currently serves on the board of directors of SteadyMed Therapeutics, Inc., a publicly-traded company, as well as Oscillari, LLC and Flow Pharma, Inc. Dr. Farr is an adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.
As the President, Chief Executive Officer, e Director of Zogenix Inc, the total compensation of Stephen Farr at Zogenix Inc is $10,346,800. There are no executives at Zogenix Inc getting paid more.
Stephen Farr is 61, he's been the President, Chief Executive Officer, e Director of Zogenix Inc since 2015. There are 6 older and 16 younger executives at Zogenix Inc. The oldest executive at Zogenix Inc is Cam Garner, 71, who is the Independent Chairman of the Board.
Stephen's mailing address filed with the SEC is 5858 Horton St #455, Emeryville, CA 94608, USA.
Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo, eJesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: